Palisade Bio Soars on Breakthrough Ulcerative Colitis Data: What Investors Need to Know
Listen up, folks! The market's buzzing today, and one stock is stealing the spotlight: Palisade Bio, Inc. (NASDAQ: PALI). As of this writing, PALI is up a jaw-dropping 32.2%, and the catalyst? A sizzling update on their lead drug, PALI-2108, which just posted a...




